Biogen
NEWS
Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche. Under the terms of the deal, Roche will pay Amunix $40 million upfront.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
According to an analysis conducted on Jan. 1, more than 250 drugs manufactured by different companies saw price increases.
Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.
The company indicated it is shutting down its gosuranemab program for PSP and other primary tauopathies.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
Biogen’s plan to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease is being met with hope for a needed therapy for a dreaded disease, but also some skepticism regarding its long-term efficacy and, ultimately, potential.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
JOBS
IN THE PRESS